<DOC>
	<DOCNO>NCT01273948</DOCNO>
	<brief_summary>This randomize , open-label , active-control Phase II pilot trial bavituximab combine ribavirin initial treatment chronic HCV genotype 1 infection . Eligible patient normal coagulation , hematological , renal function undergo screening/washout period 28 day , follow randomization receive weekly bavituximab PEG-IFN alpha-2a therapy 12 week , twice-daily ribavirin . The primary endpoint study proportion patient show great equal 2-log10 IU reduction plasma HCV RNA level 12 week treatment ( early virological response ; EVR ) . Secondary endpoint include proportion patient undetectable HCV RNA level 12 week treatment ; proportion patient show reduction HCV RNA level great equal 2 log10 IU 4 week treatment , viral kinetics individual patient time , comprehensive evaluation safety tolerability bavituximab infusion .</brief_summary>
	<brief_title>Pilot Trial Bavituximab Combined With Ribavirin Initial Treatment Chronic HepC Virus Genotype 1 Infection</brief_title>
	<detailed_description>Primary Objective : The primary objective study assess effect 12 week initial treatment bavituximab versus PEG-IFN , combine ribavirin , plasma HCV RNA level patient chronic HCV genotype 1 infection .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Male female age 18 65 year 2 . Chronic hepatitis C virus ( HCV ) genotype 1 infection 3 . HCV RNA level &gt; 10,000 IU/mL 4 . Chronic HCV infection , define : Previous documentation positive HCV serology ( HCV antibody RNA ) least 6 month ( 24 week ) previously , Positive HCV serology ( HCV antibody RNA ) prior remote ( 6 month previously ) risk factor acquisition HCV Historical biopsy consistent chronic HCV infection 5 . No clinically significant abnormality hematology , coagulation , chemistry variable : Hemoglobin &gt; 12 g/dL woman ; &gt; 13 g/dL men Total white cell count &gt; 3000/mm3 absolute neutrophil count &gt; 1500/mm3 Platelets &gt; 100,000/mm3 Prothrombin time ( PT ) and/or international normalize ratio ( INR ) less equal 1.2 time local upper limit normal ( ULN ) Conjugated ( direct ) bilirubin less equal 1.5 time ULN Serum creatinine within normal limit Thyroidstimulating hormone ( TSH ) free thyroxine ( T4 ) within normal limit 6 . Female patient : negative urine pregnancy test 7 . Ability provide inform consent 1 . Previous interferonbased antiviral therapy chronic HCV infection 2 . Previous treatment know immunogenic drug 3 . Concomitant human immunodeficiency ( HIV ) hepatitis B virus ( HBV ) infection 4 . Cause liver disease chronic HCV infection , autoimmune alcoholic liver disease 5 . Decompensated clinical liver disease , include history encephalopathy , bleed esophageal gastric varix , ascites 6 . Recipient liver solidorgan transplantation 7 . Evidence clinically significant bleeding , define gross hematuria , hemoptysis , gastrointestinal bleeding 8 . History bleed diathesis coagulopathy ( eg , von Willebrand disease hemophilia ) 9 . History thromboembolic event ( eg , deepvein thrombosis [ DVT ] pulmonary embolism ) . Previous central venous catheterrelated thrombosis acceptable resolution record least 12 month enrollment . 10 . Requirement concurrent treatment oral parenteral anticoagulant hormone ( estrogencontaining contraceptive , hormone replacement , antiestrogen agent , progestin ) 11 . Condition require daily therapy antiplatelet agent ( eg , thienopyridines , dipyridamole , cilostazol ; cardiovascular prophylaxis aspirin allow ) corticosteroid 12 . Investigational therapy within 28 day first plan dose study drug 13 . Major surgery within 28 day first plan dose study drug 14 . Uncontrolled intercurrent disease ( eg , diabetes , hypertension , thyroid disease ) 15 . Ongoing angina pectoris symptom coronary artery disease ( CAD ) ; history stroke , transient ischemic attack ( TIA ) 16 . History suicidal ideation attempt 17 . Condition require treatment ( past current ) coumarintype agent 18 . Cardiac arrhythmia require medical therapy 19 . Serious nonhealing wound ( include wound heal secondary intention , ulcer , bone fracture ) 20 . Cancer , autoimmune disease , disease concurrent therapy know cause significant alteration immune function ( corticosteroid allow study enrollment study treat AE ) 21 . Female patient female partner male patient : pregnancy , lactation , inability/unwillingness practice effective contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>